CHF Solutions, Inc. Enters the German Market
July 12 2018 - 8:30AM
CHF Solutions, Inc. (NASDAQ:CHFS), today announces it has
entered into the German market by expanding a relationship with
HSC-Medical, GmbH, a business solutions resource based in Germany.
HSC-Medical will serve as a fulfillment house and logistical
support for CHF Solutions, while the company’s current
international sales team will provide direct sales support in
Germany. This is the first entry for the company into the
German market.
“We continue to expand into the European market, as planned,”
said John Erb, Chairman and CEO of CHF Solutions. “We believe
strongly that physicians across the globe will benefit from using
the Aquadex FlexFlow system to manage fluid overload, and we are
gratified that we continue to find excellent partners to help us
grow our international sales opportunities.”
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device
company focused on commercializing the Aquadex FlexFlow system for
Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for
temporary (up to eight hours) ultrafiltration treatment of patients
with fluid overload who have failed diuretic therapy, and extended
(longer than 8 hours) ultrafiltration treatment of patients with
fluid overload who have failed diuretic therapy and require
hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom
having received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance
through science, collaboration, and innovative medical
technology. CHF Solutions is a Delaware corporation
headquartered in Minneapolis, Minnesota with wholly owned
subsidiaries in Australia and Ireland. The company has been listed
on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including without limitation, the statement
regarding the benefits from using the Aquadex FlexFlow for
physicians across the globe. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our recently announced strategic realignment, the possibility that
we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com
-or- Bret Shapiro Managing Partner CORE IR 516-222-2560
brets@coreir.com www.coreir.com
MEDIA Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024